Richard Nolan Townsend sold $40k of LXEO
Chief Executive Officer at Lexeo Therapeutics, Inc.. 5,000 shares at an average of $8.10, traded Oct 10, 2024, filed Oct 15, 2024.
Score components
- +25RoleCEO
- +6Trade size$40k at market
- 0Share of holdings soldSold 4.0% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -12.9%, 3m -35.0%, 6m -71.4%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-24-025110, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 10, 2024 | MOption exercise Common Stock10b5-1 | +5,000 | $2.33 | $12k | 125,695 | Oct 15, 2024 |
| Oct 10, 2024 | SOpen-market sale Common Stock10b5-1 | -5,000 | $8.10 | $40k | 120,695 | Oct 15, 2024 |
| Oct 10, 2024 | MOption exercise Stock Option (right to buy)derivative10b5-1 | -5,000 | $0.00 | $0 | 123,655 | Oct 15, 2024 |
Related signals
Other insiders at Lexeo Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 40Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $17k 3,345 shares | -1% | |
| 35Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $6,464 1,304 shares | -1% | |
| 37Weak | Lexeo Therapeutics, Inc. | Louis Edward Tamayo Chief Financial Officer | $20k 4,117 shares | -4% | |
| 45Moderate | Lexeo Therapeutics, Inc. | Narinder Pal Bhalla Chief Medical Officer | $99k 22,306 shares | -21% | |
| 50Moderate | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $116k 25,947 shares | -6% | |
| 35Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $21k 4,666 shares | -3% | |
| 37Weak | Lexeo Therapeutics, Inc. | Louis Edward Tamayo Chief Financial Officer | $21k 4,641 shares | -5% | |
| 33Weak | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $17k 3,342 shares | -1% | |
| 28Weak | Lexeo Therapeutics, Inc. | Jose Manuel Otero Chief Operating Officer | $6,606 1,302 shares | -1% | |
| 24Weak | Lexeo Therapeutics, Inc. | Richard Nolan Townsend Chief Executive Officer | $313k 55,000 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.